Hexametaphosphate as a Potential Therapy for the Dissolution and Prevention of Kidney Stones: Supplementary Information

Thomas E Robinson^{1,2}, Erik A B Hughes¹, Oliver J Wiseman³, Sarah A Stapley², Sophie C Cox¹, Liam M Grover¹

¹School of Chemical Engineering, University of Birmingham, Edgbaston, B15 2TT, UK

²Royal Centre for Defence Medicine, Birmingham Research Park, Vincent Drive, Edgbaston, B15 2SQ, UK

³Cambridge University Hospital, Cambridge, CB2 0QQ, UK



Supplementary Figure 1: X-ray diffraction patterns of calcium oxalate A) immediately after preparation, B) after maturation for 3 days, and C) after reprecipitation following treatment with citrate, confirming these species as the monohydrate. Patterns of precipitated calcium phosphate confirm the formation of hydroxyapatite D) immediately after precipitation and E) after 3 days of maturation. Reference patterns were obtained from the International Centre for Diffraction Data (ICDD); calcium oxalate monohydrate (PDF 00-020-0231) and hydroxyapatite (PDF 01-074-9761).



Supplementary Figure 2: Calibration curves of 600 nm light absorbance and concentration for A) calcium oxalate, B) calcium phosphate and C) calcium carbonate, formed in deionised water. Note that $CaCO_3$ is sparingly soluble in deionised water, thus concentrations below 4 mM give the same reading as deionised water. Figures show mean \pm SD (n=3) and a linear regression.



Supplementary Figure 3: Calibration curve of 600 nm light absorbance and concentration for calcium oxalate formed in artificial urine



Supplementary Figure 4: The prevention (closed circles) and dissolution (open circles) of calcium carbonate by HMP. Dashed line indicates a Ca:HMP ratio of 1:3. Mean \pm SD (n=3).



Supplementary Figure 5: Representative 2D cut through images of microCT scans of stones before and after treatment.